Can trametinib and dabrafenib treat bowel cancer?

According to the prescribing guidelines for Trametinib (Trametinib has a clear limitation of use: due to known inherent resistance to BRAF inhibition, Trametinib is not suitable for the treatment of patients with colorectal cancer. Trametinib is a MEK inhibitor that inhibits intracellular signaling pathways by targeting MEK kinase to prevent the growth and spread of tumor cells. Dabrafenib is a BRAF inhibitor that blocks the growth and spread of cancer cells with BRAF V600 mutations by targeting them.

Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. The combination of trametinib and dabrafenib produced greater growth inhibition of BRAF V600 mutation-positive tumor cell lines in vitro and prolonged inhibition of tumor growth in BRAF V600 mutation-positive tumor xenografts compared with either agent alone. However, in the case of BRAF mutant colorectal cancer, induction of EGFR-mediated MAPK pathway reactivation has been identified as an intrinsic resistance mechanism to BRAF inhibitors.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance, but it may only be available to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a 2mg*30 tablet of a generic drug produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate).